It started as a fight for my own life. It has become a mission for all of us.

Built from lived experience

The wrong diagnosis.

I was first told I had type 2 diabetes, because of my age. That diagnosis was later proven wrong. Months went by, and my body paid for it: exhaustion, pain, a slow burn from the inside. When the right diagnosis finally came, LADA (a slow-onset form of type 1), my HbA1c had reached 14.2%.

Then came the right treatment: insulin (basal and bolus), dosed well.
It took nearly 18 months to bring my HbA1c below 12% and to start feeling better.

That is what GlukoLife is built on. With this disease, the right treatment changes everything, and the insulin dosage above all.

Getting the insulin dosage right changes everything.

Our commitment

Lorinda’s story ended differently.

In February 2017, my mother-in-law, Lorinda M., passed away from complications of type 1 diabetes (LADA), the same subtype as mine.

I believe that better tools to manage insulin day to day could have spared her this tragedy, and given her more years with us.

I began building what I needed and she did not have: technology designed to help decide each insulin dose for each person’s condition, aiming to reduce the risk of hypoglycemia and hyperglycemia, because both can have serious consequences in the long term.

The GlukoLife project, in its entirety, is dedicated to her memory.

The challenge

A dosing decision, several times a day.

People treated with insulin decide on a dose several times a day, weighing the meal, the insulin still active, and where glucose is heading. A glucose sensor or a finger-prick test tells you where glucose is right now. It cannot tell you what a dose will do over the next hours.

• Estimating the right dose before each meal.
• Highs after meals, lows during physical activity.
• Stress, sleep, illness, heat, exercise, and other factors, which all change how insulin works.

From 2015 to 2018, the apps I used to log my blood sugar felt limited and incomplete. The more options I looked for, the messier the interface and experience became. I tested more than 40 apps before concluding that I had to do something.

First hand-drawn concept

The first screen.

It taught me that interface and experience matter, and that a screen could adapt to each person: someone who takes insulin (type 1, or type 2 with insulin) does not need the same screen as someone who does not (type 2 without insulin). In 2018, I drew the first GlukoLife screen by hand.

The + button opens to reveal the services you log: meals, insulin, glucose, sleep, and activity.

Every meal is a decision. We want to make it lighter for everyone.

First algorithm

The first version of the algorithm.

The first version of the GlukoLife insulin-dose calculation algorithm was developed. Early work analysed continuous glucose monitor (CGM) patterns and prototyped the first predictive insulin-dose logic.

Our mission

Build a helpful insulin-dosing tool, and make it accessible to all.

GlukoLife was incorporated in Québec in 2021, a century after insulin was discovered in Canada.
Our tool is designed to learn how each person’s glucose behaves, so that it becomes unique to every patient.

• PersonalDesigned to adapt to each person.
• AccessibleSimple, easy to use.
• HelpfulDesigned to reduce guesswork at each dose.

A century after insulin was created, we will help people dose it well.

Protecting the idea

First provisional patent application.

The core technology has been the subject of provisional patent applications since 2022.

Accelerator · September 2022

BAJ accelerator, Cornell Tech.

GlukoLife joined the September 2022 cohort of the BAJ accelerator in New York, a program run with the Jacobs Technion-Cornell Institute at Cornell Tech that offers early-stage companies expert-led workshops, coaching, and networking.

Incubation support

CEIM backed the prototype.

A grant administered by the Centre d’entreprises et d’innovation de Montréal (CEIM) and funded by Québec’s Ministry of Economy, Innovation and Energy. It contributed to functional prototype development and continued research.

Medteq+ consortium

Accepted into Medteq+.

GlukoLife was accepted into the Medteq+ consortium, which supports academic medical research partnerships. Its IMPACT program supports projects that pair a company with an academic laboratory.

Public data

The numbers say this is not only my story.

Sources: International Diabetes Federation (IDF) Diabetes Atlas, 11th ed. (2025), all editions, Foster et al. 2019, DCCT/EDIC, UKPDS 35.

What we are building · Populations we are studying

Dose guidance for people treated with insulin.

GlukoLife is developing software as a medical device. It is designed to recommend mealtime boluses and insulin dose adjustments to correct hyperglycemia, and to explain why. The person decides and doses by their usual method. The software does not deliver insulin or control a device that delivers insulin.

Software in development. Not approved or cleared by any regulatory authority and not available for clinical use.

Populations we are studying. Future intended-use populations remain subject to clinical evidence and regulatory review.

• Type 1 diabetesChildren, adolescents, and adults
• Insulin-treated type 2Adults using mealtime or correction insulin
• PregnancyPeople using insulin during pregnancy
• Older adultsPeople managing insulin later in life

• Technology readinessTRL 6Technology Readiness Level 6: integrated prototype demonstrated in a relevant environment.
• ProtectionPatent pendingCore aspects of the technology. The latest provisional application was filed in June 2026.

The next step

From prototype toward a human clinical study.

Before any use in care, the work must be tested carefully with the right partners and under regulatory oversight. GlukoLife intends to work with:

1. Canada: Health Canada, for a medical device licence.
2. United States: the FDA, for feedback as the evidence matures.
3. Europe: CE marking, possibly later.